Vaccinex is a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat diseases and conditions with unmet medical needs. Co.'s main platform technologies include: semaphorin 4D (SEMA4D) antibody platform, which is the application of its knowledge of SEMA4D biology to develop its main product candidate pepinemab for the treatment of various indications, including cancer and neuroinflammatory and neurodegenerative diseases; and ActivMAb antibody discovery platform, which is a proprietary human antibody discovery platform based on a method for expressing libraries of human monoclonal antibodies on the surface of mammalian pox viruses. The VCNX stock yearly return is shown above.
The yearly return on the VCNX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the VCNX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|